# The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.

> **NCT05329844** · NA · COMPLETED · sponsor: **AET Laboratories Private Limited** · enrollment: 66 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Vildagliptin 50 MG

## Key facts

- **NCT ID:** NCT05329844
- **Lead sponsor:** AET Laboratories Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-03
- **Final completion:** 2015-04
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2022-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05329844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05329844, "The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05329844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*